Patents by Inventor Richard A. Lerner

Richard A. Lerner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190177418
    Abstract: The invention provides TrkB agonist antibodies or antigen-binding fragments that specifically enhance TrkB signaling activities. The invention also provides therapeutic methods of using such antibodies for promoting survival and regeneration of retinal ganglion cells, and for treating or preventing subjects suffering from or at risk of developing various neurodegenerative conditions such as glaucoma.
    Type: Application
    Filed: May 2, 2017
    Publication date: June 13, 2019
    Inventors: Richard A. Lerner, Ronald M. Lindsay, Jia Xie
  • Publication number: 20190016774
    Abstract: The invention provides combinatorial peptide or polypeptide libraries that can become membrane tethered once expressed in cells. The invention additionally provides methods for selecting peptide modulators (e.g., agonists) of GPCRs from the combinatorial libraries of the invention. The invention also provides novel GPCR polypeptide modulators, e.g., biased polypeptide agonists of the glucagon-like peptide 1 receptor (GLP-1R). The invention further provides methods of promoting insulin sensitivity, lowering blood glucose, and reducing body weight as well as methods for treating various diseases such as diabetes and obesity.
    Type: Application
    Filed: April 1, 2016
    Publication date: January 17, 2019
    Inventors: Richard A. LERNER, Hongkai ZHANG, Patricia MC DONALD, Jia XIE, Emmanuel STURCHLER
  • Publication number: 20180298051
    Abstract: The present invention provides methods for generating functional derivatives of effector polypeptides (e.g., hormones and receptor ligands) embedded in a different protein scaffold (e.g., antibody scaffolds). The methods involve modifying the effector polypeptide with a combinatorial library of terminal linker sequences, inserting the modified sequences into the host scaffold, and then selecting functional derivatives from the library of modified polypeptide sequences embedded in the host scaffold. As exemplifications, the invention also provides specific functional derivatives of leptin, scFSH and scRelaxin embedded in an antibody scaffold, as well as therapeutic applications of such functional fusion molecules.
    Type: Application
    Filed: December 1, 2015
    Publication date: October 18, 2018
    Inventors: Yingjie Peng, Richard A. Lerner, Ronald M. Lindsay
  • Publication number: 20180119133
    Abstract: The invention provides methods for identifying binding partners (e.g., peptide ligands) that binds to a target protein (e.g., a cellular receptor). The methods entail co-localized expression of the target protein and candidate binding partners, and selection of binding partners based on their proximity in the plasma membrane.
    Type: Application
    Filed: October 16, 2015
    Publication date: May 3, 2018
    Inventors: Richard A. Lerner, Hongkai Zhang, Jia Xie
  • Publication number: 20180002425
    Abstract: The invention provides methods for identifying protein modulators (e.g., antibody agonists) of eukaryotic cells. The methods typically involve expressing a combinatorial agent library (e.g., via lentiviral vectors) inside a eukaryotic cell type (e.g., a mammalian cell) and then directly selecting for agents (e.g., antibodies) that are agonist of a target molecule (e.g., a signaling receptor) that modulates a phenotype of or elicits a cellular response in the cell. Some related methods involve co-culturing a cell expressing a combinatorial agent library and a second cell, and then selecting agents that modulate a phenotype of or elicit a cellular response in the second cell. Preferably, the agents are antibodies and are introduced into and expressed in the starting cells under conditions each individual cell expresses no more than 3 different members of the antibody library.
    Type: Application
    Filed: August 8, 2017
    Publication date: January 4, 2018
    Inventors: Hongkai Zhang, Ian A. Wilson, Richard A. Lerner
  • Publication number: 20170320921
    Abstract: The invention relates to a group of isolated polypeptides and derivatives that can bind genetically to immunoglobulins or antibodies. The invention also relates to industrial and other applications of these molecules, e.g., antibody purifications.
    Type: Application
    Filed: February 2, 2015
    Publication date: November 9, 2017
    Inventors: Rajesh Grover, Richard Lerner, Ian Wilson, Xueyong Zhu
  • Patent number: 9738719
    Abstract: Methods for Identifying protein modulators of eukaryotic cells by expressing a combinatorial library of potential agonists inside a eukaryotic cell and then directly selecting for an agonist of a target molecule. Some methods involve co-culturing a cell expressing a combinatorial library of potential agonists and a second cell, and then selecting agents that modulate a phenotype of or a desired cellular response in the second cell. Preferably, the agonists are antibodies introduced into and expressed in the starting cells, such as agonist anti-EpoR, anti-TpoR, or G-CSFR antibodies. Also disclosed are methods for selecting from combinatorial antibody libraries bispecific antibodies that can regulate cell phenotypes.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: August 22, 2017
    Assignee: The Scripps Research Institute
    Inventors: Hongkai Zhang, Ian A. Wilson, Richard A. Lerner
  • Patent number: 9593150
    Abstract: Provided herein methods of alleviating the symptoms of multiple myeloma in a patient or subject in need thereof, methods of treating multiple myeloma in a patient or subject, and methods of preventing development of multiple myeloma in a patient at risk thereof, such as a patient with monoclonal gammopathy of undetermined significance (MGUS), which methods include administering an agent effective to treat a Mycoplasma infection. The invention also relates to a new class of antigen, MG281 protein {also referenced as Protein M), that binds to various immunoglobulins with high affinity, and their uses in purifying immunoglobulins. The invention additionally relates to using MG281 protein and analog or derivative molecules for treating autoimmune diseases. Further provided are antigens and antibodies for use in the disclosed methods, and the identification of molecules that bind to MG281 protein.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: March 14, 2017
    Assignee: The Scripps Research Institute
    Inventors: Rajesh Grover, Richard Lerner, Ian Wilson, Xueyong Zhu
  • Publication number: 20150316561
    Abstract: Methods for Identifying protein modulators of eukaryotic cells by expressing a combinatorial library of potential agonists inside a eukaryotic cell and then directly selecting for an agonist of a target molecule. Some methods involve co-culturing a cell expressing a combinatorial library of potential agonists and a second cell, and then selecting agents that modulate a phenotype of or a desired cellular response in the second cell. Preferably, the agonists are antibodies introduced into and expressed in the starting cells, such as agonist anti-EpoR, anti-TpoR, or G-CSFR antibodies. Also disclosed are methods for selecting from combinatorial antibody libraries bispecific antibodies that can regulate cell phenotypes.
    Type: Application
    Filed: August 16, 2013
    Publication date: November 5, 2015
    Inventors: Hongkai Zhang, Ian A. Wilson, Richard A. Lerner
  • Publication number: 20150246953
    Abstract: Provided herein methods of alleviating the symptoms of multiple myeloma in a patient or subject in need thereof, methods of treating multiple myeloma in a patient or subject, and methods of preventing development of multiple myeloma in a patient at risk thereof, such as a patient with monoclonal gammopathy of undetermined significance (MGUS), which methods include administering an agent effective to treat a Mycoplasma infection. The invention also relates to a new class of antigen, MG281 protein {also referenced as Protein M), that binds to various immunoglobulins with high affinity, and their uses in purifying immunoglobulins. The invention additionally relates to using MG281 protein and analog or derivative molecules for treating autoimmune diseases. Further provided are antigens and antibodies for use in the disclosed methods, and the identification of molecules that bind to MG281 protein.
    Type: Application
    Filed: July 16, 2013
    Publication date: September 3, 2015
    Inventors: Rajesh Grover, Richard Lerner, Ian Wilson, Xueyong Zhu
  • Publication number: 20150079172
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D2 receptor signaling systems.
    Type: Application
    Filed: April 14, 2013
    Publication date: March 19, 2015
    Inventors: Sharon Mates, Robert Davis, Peng Li, Lawrence Wennogle, Richard A. Lerner
  • Patent number: 8338107
    Abstract: The present invention relates to a method for isolating from the immunological gene repertoire a gene coding for a receptor having the ability to bind a preselected ligand. Receptors produced by the gene isolated by the method, particularly catalytic receptors, are also contemplated.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: December 25, 2012
    Assignees: Scripps Research Institute, Medical Research Institute, Catalyst Assets LLC
    Inventors: William D. Huse, Gregory P. Winter, Lutz Riechmann, Joseph A. Sorge, Richard A. Lerner
  • Patent number: 8318172
    Abstract: The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against a version of a target moiety having one or more unnatural amino acid which antibody is cross reactive with the natural target moiety.
    Type: Grant
    Filed: February 7, 2009
    Date of Patent: November 27, 2012
    Assignee: The Scripps Research Institute
    Inventors: Jan Grunewald, Meng-Lin Tsao, Roshan Perera, Richard A. Lerner, Vaughn V. Smider, Peter G. Schultz
  • Patent number: 8252902
    Abstract: The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: August 28, 2012
    Assignee: The Scripps Research Institute
    Inventors: Carlos F. Barbas, Christoph Rader, Subhash C. Sinha, Richard A. Lerner
  • Publication number: 20120082997
    Abstract: A composition of matter which comprises a non-gaseous nitrogen containing compound; and a spore of a micro-organism. A method of determining a source of a material the material being an explosive or a substance used in the preparation of the explosive, the material comprises a spore of a micro-organism uniquely associated with the material, the method comprises inducing the spore to transform into a vegetative micro-organism and identifying the micro-organism as being associated with the material, thereby determining the source of the material.
    Type: Application
    Filed: June 7, 2011
    Publication date: April 5, 2012
    Applicant: Technion Research & Development
    Inventors: Ehud Keinan, Richard A. Lerner
  • Patent number: 7985841
    Abstract: Filamentous phage comprising a matrix of cpVIII proteins encapsulating a genome encoding first and second polypeptides of an antogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a filamentous phage coat protein membrane anchor domain fused to at least one of the polypeptides.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: July 26, 2011
    Assignee: The Scripps Research Institute
    Inventors: Angray Kang, Carlos F. Barbas, Richard A. Lerner
  • Publication number: 20110052525
    Abstract: The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against a version of a target moiety having one or more unnatural amino acid which antibody is cross reactive with the natural target moiety.
    Type: Application
    Filed: February 7, 2009
    Publication date: March 3, 2011
    Applicant: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Jan Grunewald, Meng-Lin Tsao, Roshan Perera, Richard A. Lerner, Vaughn V. Smider, Peter G. Schultz
  • Patent number: 7858359
    Abstract: The present invention relates to a method for isolating from the immunological gene repertoire a gene coding for a receptor having the ability to bind a preselected ligand. Receptors produced by the gene isolated by the method, particularly catalytic receptors, are also contemplated.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: December 28, 2010
    Assignees: Stratagene, Medical Research Council
    Inventors: William D. Huse, Gregory P. Winter, Lutz Riechmann, Joseph A. Sorge, Richard A. Lerner
  • Publication number: 20100216659
    Abstract: The present invention provides methods for identifying cognate binding pairs from two libraries of biomolecules (e.g., polypeptides). The methods typically involve displaying a first library of candidate biomolecules (e.g., receptors or epitopes) on a first replicable genetic package (e.g., a cell surface display platform) and displaying a second library of candidate biomolecules (e.g., ligands) on a second replicable genetic package (e.g., a phage display platform), contacting the first library with the second library, and then selecting members of the first library to which a member of the second library is bound. Also provided in the invention are compositions and kits for carrying out the methods of the invention.
    Type: Application
    Filed: June 16, 2008
    Publication date: August 26, 2010
    Applicant: The Scipps Research Institute
    Inventors: Diana R. Bowley, Teresa Jones, Dennis R. Burton, Richard A. Lerner
  • Publication number: 20100210473
    Abstract: The present invention provides methods for identifying cognate binding pairs from two libraries of biomolecules (e.g., polypeptides). The methods typically involve displaying a first library of candidate biomolecules (e.g., receptors or epitopes) on a first replicable genetic package (e.g., a cell surface display platform) and displaying a second library of candidate biomolecules (e.g., ligands) on a second replicable genetic package (e.g., a phage display platform), contacting the first library with the second library, and then selecting members of the first library to which a member of the second library is bound. Also provided in the invention are compositions and kits for carrying out the methods of the invention.
    Type: Application
    Filed: January 12, 2010
    Publication date: August 19, 2010
    Applicant: The Scripps Research Institute
    Inventors: Diana R. Bowley, Teresa Jones, Dennis R. Burton, Richard A. Lerner